Trial Profile
A Phase 1, Open-Label, Multicenter, Non-Randomized, Dose Escalation Study to Evaluate the Safety and Tolerability of SHR-1316 in Subjects With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Adebrelimab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Atridia
- 07 Aug 2019 Status changed from active, no longer recruiting to completed.
- 02 Jul 2019 Planned End Date changed from 30 May 2019 to 30 Sep 2019.
- 26 Feb 2019 Planned End Date changed from 30 Mar 2019 to 30 May 2019.